Campbell & CO Investment Adviser LLC Buys New Position in Quanterix Co. (NASDAQ:QTRX)

Campbell & CO Investment Adviser LLC bought a new stake in shares of Quanterix Co. (NASDAQ:QTRXFree Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 16,403 shares of the company’s stock, valued at approximately $448,000.

Other hedge funds also recently modified their holdings of the company. AJOVista LLC purchased a new position in shares of Quanterix during the fourth quarter valued at approximately $81,000. DekaBank Deutsche Girozentrale bought a new stake in Quanterix during the third quarter worth $125,000. Picton Mahoney Asset Management bought a new stake in Quanterix during the fourth quarter worth $139,000. Quest Partners LLC bought a new stake in Quanterix during the fourth quarter worth $240,000. Finally, Los Angeles Capital Management LLC bought a new stake in Quanterix during the fourth quarter worth $285,000. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on QTRX. Scotiabank lifted their price target on Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a report on Monday, March 4th. Canaccord Genuity Group dropped their price target on Quanterix from $32.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, April 29th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $30.60.

Read Our Latest Stock Analysis on QTRX

Quanterix Price Performance

Shares of QTRX opened at $18.10 on Tuesday. The firm has a market cap of $692.69 million, a PE ratio of -18.85 and a beta of 1.50. The stock’s fifty day moving average price is $17.28 and its two-hundred day moving average price is $22.24. Quanterix Co. has a 1 year low of $14.26 and a 1 year high of $29.70.

Quanterix (NASDAQ:QTRXGet Free Report) last issued its earnings results on Tuesday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.07. The firm had revenue of $32.07 million for the quarter, compared to analyst estimates of $31.72 million. Quanterix had a negative return on equity of 10.39% and a negative net margin of 28.82%. Sell-side analysts anticipate that Quanterix Co. will post -0.86 earnings per share for the current fiscal year.

About Quanterix

(Free Report)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

See Also

Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRXFree Report).

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.